Constellium SE (CSTM) - What Are Researchers Saying About This Stock?

Key Points

• Analyst consensus is “Moderate Buy”: Four analysts rate Constellium a buy and four recommend holding, with an average 12-month price target of $33.33 versus the reported $25.30 share price.
• Recent analyst views were mixed: UBS and Wells Fargo maintained positive ratings while lowering their targets, whereas Zacks Research downgraded the stock to hold and Barclays initiated coverage with an equal-weight rating.
• Recent performance exceeded expectations: Constellium reported quarterly EPS of $1.04, beating estimates of $0.86, while revenue rose 30.7% year over year to $2.75 billion. Institutional investors own approximately 92.59% of the stock.

Constellium SE (NYSE:CSTM - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $33.33.

Several equities research analysts recently commented on the stock. UBS Group cut their price objective on shares of Constellium from $34.00 to $32.00 and set a "buy" rating on the stock in a research report on Thursday, October 8th. Zacks Research cut Constellium from a "strong-buy" rating to a "hold" rating in a report on Tuesday, October 6th. Wells Fargo & Company dropped their price target on Constellium from $39.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, September 18th. Weiss Ratings reissued a "hold (c+)" rating on shares of Constellium in a research report on Monday, September 28th. Finally, Barclays initiated coverage on Constellium in a research report on Wednesday. They set an "equal weight" rating and a $28.00 price target for the company.

Constellium Stock Down 1.8%

NYSE:CSTM opened at $25.30 on Thursday. Constellium has a 1 year low of $14.62 and a 1 year high of $36.99. The stock has a 50-day moving average price of $26.54 and a two-hundred day moving average price of $29.49. The stock has a market cap of $3.43 billion, a price-to-earnings ratio of 6.52 and a beta of 1.57. The company has a current ratio of 1.43, a quick ratio of 0.61 and a debt-to-equity ratio of 1.50.

Constellium (NYSE:CSTM - Get Free Report) last posted its earnings results on Wednesday, July 29th. The industrial products company reported $1.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.86 by $0.18. The business had revenue of $2.75 billion during the quarter, compared to analysts' expectations of $2.73 billion. Constellium had a return on equity of 51.66% and a net margin of 5.69%. Constellium's revenue for the quarter was up 30.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.25 EPS. As a group, equities analysts expect that Constellium will post 3.79 earnings per share for the current year.

Insider Buying and Selling at Constellium

In related news, Director Jean-Christophe Deslarzes acquired 1,490 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $27.24 per share, for a total transaction of $40,587.60. Following the purchase, the director directly owned 43,515 shares in the company, valued at approximately $1,185,348.60. This trade represents a 3.55% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Constellium

Several hedge funds and other institutional investors have recently made changes to their positions in CSTM. Encompass Capital Advisors LLC lifted its holdings in shares of Constellium by 9.2% in the fourth quarter. Encompass Capital Advisors LLC now owns 4,657,915 shares of the industrial products company's stock valued at $87,802,000 after purchasing an additional 393,640 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Constellium by 620.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,228,027 shares of the industrial products company's stock worth $79,345,000 after purchasing an additional 2,780,260 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Constellium by 894.4% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,056,336 shares of the industrial products company's stock worth $50,545,000 after purchasing an additional 1,849,554 shares during the period. SG Americas Securities LLC raised its stake in shares of Constellium by 53.6% during the 1st quarter. SG Americas Securities LLC now owns 1,497,460 shares of the industrial products company's stock worth $36,808,000 after purchasing an additional 522,725 shares during the period. Finally, Beaconlight Capital LLC boosted its holdings in shares of Constellium by 5.2% in the 4th quarter. Beaconlight Capital LLC now owns 1,339,934 shares of the industrial products company's stock worth $25,258,000 after buying an additional 66,429 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

About Constellium

Constellium SE NYSE: CSTM is a global manufacturer of advanced aluminum products and solutions. The company develops, engineers and produces aluminum rolled, extruded and shaped products for customers in the aerospace, automotive, packaging and industrial markets.

Its products include aluminum sheets, plates, coils, extrusions, structural components and automotive body systems. Constellium also supplies aluminum products used in beverage cans, bottles and other packaging applications, as well as components for aircraft structures, automotive vehicles, commercial transportation and industrial equipment.

Constellium serves customers through manufacturing and research operations across Europe, North America and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.